Last updated: June 3, 2026
Larin Fe 1.5/30 Drug Supply Chain: Key Manufacturers, Labelers, and Component Suppliers
Larin Fe 1.5/30 is a branded oral contraceptive blister-pack product (norethindrone acetate 1.5 mg plus ethinyl estradiol 30 mcg with ferrous fumarate tablets as placebos) distributed through FDA-registered commercial channels. The practical “suppliers” for this product are (1) the NDA/label holder and primary manufacturers that make the drug product and package it, and (2) upstream API and excipient manufacturers that supply controlled, cGMP-grade components used to manufacture the final blister packs.
Who makes Larin Fe 1.5/30 (NDA holder, labeler, and drug-product manufacturers)?
Featured snippet answer: Larin Fe 1.5/30 is marketed in the US under the Pfizer consumer brands portfolio, with drug product manufacturing and packaging conducted by FDA-registered sites listed on the product’s FDA Drug Listing.
How to identify the “labeler” that controls commercial supply
FDA’s drug listing identifies:
- The labeler (marketing authorization holder for listing purposes)
- The manufacturing and packaging site(s) tied to the listed NDC(s)
For branded combination OCs, the “supplier” buyers typically need for procurement, qualification, and continuity planning is the firm listed as the drug-product manufacturer for each NDC strength/package configuration.
What active pharmaceutical ingredients (API) suppliers make norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg?
Featured snippet answer: The APIs are typically sourced from multiple qualified global API suppliers because branded OC supply chains often use alternative sites for batch continuity. The reliable way to map “API suppliers” is through:
- FDA DMF cross-references (where held and used for drug product manufacture)
- cGMP supplier qualification records tied to the specific drug-product manufacturer sites listed for each NDC
Upstream API inputs
- Norethindrone acetate API
- Ethinyl estradiol API
- Ferrous fumarate (used for iron placebo tablets)
Why “API supplier” naming is harder than drug-product sites
Drug listings commonly disclose drug-product manufacturing sites, not the API vendor brands. API vendors are more often identifiable through DMFs and DMF-referenced manufacturing processes.
Which excipient and blister-pack component suppliers are involved in Larin Fe 1.5/30?
Featured snippet answer: For oral contraceptive blister packs, the material category “suppliers” most often fall into:
- Tablet excipients (binders, lubricants, disintegrants)
- Film coating system (if used for active tablets, sometimes color differentiation)
- Blister packaging components (PVC/PVDC or alternative film, aluminum foil lidding)
- Ink and overprint systems used for traceability and patient-use labeling
Packaging suppliers that matter operationally
For continuity and regulatory tech transfer, the procurement-critical upstream components are:
- Blister film and foil suppliers
- Carton/insert suppliers
- Serialization or print/ink systems used in packaging lines (as applicable)
What is the supply footprint by NDC for Larin Fe 1.5/30?
Featured snippet answer: Larin Fe 1.5/30 has multiple NDCs tied to different pack sizes and distribution configurations. Each NDC can map to different manufacturing/packaging sites on FDA drug listings.
NDC-level supplier mapping (what to extract from FDA records)
For each Larin Fe 1.5/30 NDC, the supply chain view is:
- Labeler on FDA listing
- Drug product manufacturing site
- Packaging site
- Marketed strength and dosage form linkage
Do Larin Fe 1.5/30 suppliers differ from other brands with norethindrone acetate/ethinyl estradiol?
Featured snippet answer: Yes, drug-product manufacturing sites frequently differ between branded equivalents even when the active ingredient set is the same, because:
- NDA label-specific manufacturing assignments change over time
- Contract manufacturers are selected per batch and facility capacity
- Blister pack line qualification differs per labeler and NDC
Common comparison set in this therapeutic space
Other norethindrone acetate/ethinyl estradiol combination OCs in the market may use different packaging lines and different drug-product sites even if they share similar API categories.
What manufacturing and packaging constraints affect Larin Fe 1.5/30 supply continuity?
Featured snippet answer: Continuity risks for combination oral contraceptives concentrate in three areas:
- Capacity at the drug-product manufacturing site(s)
- Blister packaging line throughput and film/foil procurement
- API supply continuity for norethindrone acetate and ethinyl estradiol
Regulatory constraints that lock in suppliers
- Site-specific cGMP compliance and validation for tablet compression and coating (if used)
- Blister packaging integrity and stability qualification for the exact dosage form
- Label-specific packaging configuration and patient instructions
How does the supply chain map to FDA listings and what records disclose suppliers?
Featured snippet answer: Supplier identification for Larin Fe 1.5/30 is most directly disclosed through FDA records that list:
- Drug listing manufacturer/packager sites for each NDC
- DMF-linked API usage by the drug-product manufacturer(s) (when DMF is referenced)
- Registered establishment information (facility status)
Primary records used in supplier mapping
- FDA “Drug Listing” for NDC labeler and manufacturing/packaging sites
- FDA “Drug Establishments” registry for facility status and authorization
- DMF database and references for API manufacturing relationships (where discoverable)
Key Takeaways
- “Suppliers” for Larin Fe 1.5/30 are best defined as labeler, drug-product manufacturers, and packaging manufacturers listed per NDC in FDA drug listings.
- Upstream API supplier names (norethindrone acetate, ethinyl estradiol) are typically not fully enumerated in public drug listings; API relationships are more accurately traced via DMF references and the drug-product manufacturer’s qualified supply chain.
- Packaging material suppliers (blister film, lidding foil, inks) are procurement-critical for continuity but usually require mapping through the specific packaging manufacturer sites tied to each NDC.
FAQs
- How do I find the FDA drug listing manufacturer for a specific Larin Fe 1.5/30 NDC?
- Which FDA records show the packaging manufacturer for Larin Fe 1.5/30 blister packs?
- Can norethindrone acetate and ethinyl estradiol API suppliers be identified from DMFs referenced to Larin Fe 1.5/30?
- Do packaging lines for Larin Fe 1.5/30 change across pack sizes or generics/authorized label expansions?
- What supply-chain bottlenecks typically trigger shortages for combination oral contraceptives like Larin Fe 1.5/30?
References
- U.S. Food and Drug Administration (FDA). Drug Establishment Registration and Listing.
- U.S. Food and Drug Administration (FDA). Drug Listing (NDC labeler and manufacturing/packaging site listings).
- U.S. Food and Drug Administration (FDA). Drug Master Files (DMF) database and DMF references (public-facing records where applicable).
